JP2022544075A5 - - Google Patents

Info

Publication number
JP2022544075A5
JP2022544075A5 JP2022506436A JP2022506436A JP2022544075A5 JP 2022544075 A5 JP2022544075 A5 JP 2022544075A5 JP 2022506436 A JP2022506436 A JP 2022506436A JP 2022506436 A JP2022506436 A JP 2022506436A JP 2022544075 A5 JP2022544075 A5 JP 2022544075A5
Authority
JP
Japan
Prior art keywords
cells
igg
nucleic acid
composition according
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022506436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544075A (ja
JP7668261B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044159 external-priority patent/WO2021021989A1/en
Publication of JP2022544075A publication Critical patent/JP2022544075A/ja
Publication of JP2022544075A5 publication Critical patent/JP2022544075A5/ja
Priority to JP2025066219A priority Critical patent/JP2025100724A/ja
Application granted granted Critical
Publication of JP7668261B2 publication Critical patent/JP7668261B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022506436A 2019-08-01 2020-07-30 改良された免疫療法のための細胞およびその使用 Active JP7668261B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025066219A JP2025100724A (ja) 2019-08-01 2025-04-14 改良された免疫療法のための細胞およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881467P 2019-08-01 2019-08-01
US62/881,467 2019-08-01
PCT/US2020/044159 WO2021021989A1 (en) 2019-08-01 2020-07-30 Cells for improved immunotherapy and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025066219A Division JP2025100724A (ja) 2019-08-01 2025-04-14 改良された免疫療法のための細胞およびその使用

Publications (3)

Publication Number Publication Date
JP2022544075A JP2022544075A (ja) 2022-10-17
JP2022544075A5 true JP2022544075A5 (enExample) 2023-07-14
JP7668261B2 JP7668261B2 (ja) 2025-04-24

Family

ID=74228276

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506436A Active JP7668261B2 (ja) 2019-08-01 2020-07-30 改良された免疫療法のための細胞およびその使用
JP2025066219A Pending JP2025100724A (ja) 2019-08-01 2025-04-14 改良された免疫療法のための細胞およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025066219A Pending JP2025100724A (ja) 2019-08-01 2025-04-14 改良された免疫療法のための細胞およびその使用

Country Status (11)

Country Link
US (1) US20220218748A1 (enExample)
EP (1) EP4007586A4 (enExample)
JP (2) JP7668261B2 (enExample)
KR (1) KR20220040476A (enExample)
CN (1) CN114450397A (enExample)
AU (1) AU2020323542A1 (enExample)
BR (1) BR112022001407A2 (enExample)
CA (1) CA3149395A1 (enExample)
IL (1) IL290109A (enExample)
MX (1) MX2022001383A (enExample)
WO (1) WO2021021989A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
EP4433587A2 (en) * 2021-11-15 2024-09-25 Hansa Biopharma AB Methods for enhancing adoptive cell transfer immunotherapies
AU2023383441A1 (en) 2022-11-18 2025-06-05 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof
WO2026072947A1 (en) * 2024-09-26 2026-04-02 Cyrus Biotechnology, Inc. Ides variant proteins and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003219847A1 (en) * 2002-02-21 2003-09-09 The Wistar Institute Of Anatomy And Biology Methods and compositions for reversibly controlling expression of target genes in cells
AU2004257206A1 (en) * 2003-07-10 2005-01-27 Wyeth Holdings Corporation Recombinant expression of Streptococcus pyogenes cysteine protease and immunogenic compositions thereof
CN105770871A (zh) * 2005-06-09 2016-07-20 汉莎医药有限公司 IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
WO2008051854A2 (en) * 2006-10-20 2008-05-02 Trustees Of Boston University A tunable genetic switch for regulating gene expression
US20110016548A1 (en) * 2009-07-16 2011-01-20 University Of Southern California Control of endogenous dnmt1 gene expression by exogenous binary regulatory systems
HK1220111A1 (zh) * 2013-03-05 2017-04-28 Baylor College Of Medicine 人类t淋巴细胞中类肝素酶的表达
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
EP3240797A4 (en) * 2014-12-31 2018-08-01 Development Center for Biotechnology Site-specific conjugation through glycoproteins linkage and method thereof
PL3280729T3 (pl) * 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
TN2018000212A1 (en) * 2015-12-16 2019-10-04 Amgen Inc Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
CN108697733A (zh) * 2016-01-11 2018-10-23 鲁比厄斯治疗法股份有限公司 与癌症适应症的多模式治疗性细胞体系有关的组合物和方法
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
FI127283B (en) * 2016-02-22 2018-03-15 Teknologian Tutkimuskeskus Vtt Oy Expression system for eukaryotic microorganisms
WO2018093868A1 (en) * 2016-11-16 2018-05-24 University Of Florida Research Foundation, Inc. Immunoglobulin proteases, compositions, and uses thereof
WO2018183685A1 (en) * 2017-03-29 2018-10-04 President And Fellows Of Harvard College Methods of regulating gene expression in a cell
EP3645020A4 (en) * 2017-06-30 2021-11-17 Memorial Sloan-Kettering Cancer Center COMPOSITIONS AND PROCEDURES FOR ADOPTIVE CELL THERAPY

Similar Documents

Publication Publication Date Title
AU2019218989B2 (en) Chimeric antigen receptors targeting the tumor microenvironment
JP7179030B2 (ja) Ｒｏｒ１ ｃａｒ ｔ細胞
JP7356970B2 (ja) 多重特異性抗体とその作製及び使用方法
ES3023783T3 (en) Engineered gamma delta t-cells
JP2024020298A (ja) シグレック－１５に対する抗体及びその使用方法
US7820166B2 (en) Potent T cell modulating molecules
EP3842450A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
TW201713701A (zh) 靶向ｎｙ－ｅｓｏ－１肽／ｍｈｃ複合體之構築體及其用途
CN111247241A (zh) T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法
KR20190116420A (ko) Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
IL321897A (en) Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
CN113784980B (zh) 人源化抗Claudin18.2嵌合抗原受体及其用途
TW201710294A (zh) 靶向ａｆｐ肽／ｍｈｃ複合體之構築體及其用途
CN105744955A (zh) 用于癌症治疗的包含抗ceacam1抗体和抗pd抗体的组合物
Junghans The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
CN113728007B (zh) 人源化抗叶酸受体1嵌合抗原受体及其用途
JP2013510836A (ja) コンジュゲート分子
ES2341341T3 (es) Anticuerpos terapeuticos humanizados contra las isoformas cd45.
CN114401990A (zh) 用于调节髓系细胞炎性表型的抗psgl-1组合物和方法及其用途
KR20230004510A (ko) 인간 cd45rc에 특이적인 키메라 항원 수용체 및 이의 용도
TW202342507A (zh) 抗ｓｔｅａｐ２嵌合抗原受體及其用途
JP2025534161A (ja) 線維芽細胞活性化タンパク質（ｆａｐ）ｃａｒインバリアントナチュラルキラーｔ細胞及びその使用
Perna et al. Immune-based therapeutic interventions for acute myeloid leukemia
US20250302763A1 (en) Immune engineering amplification
Mobergslien et al. Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth